Fresenius Kabi Oncology, a New Delhi based MNC, has suffered minor
setback during the second quarter ended September 2010 and its net
profit declined by 1.1 per cent to Rs. 21.91 crore from Rs. 22.16 crore in the similar period of last year. Its net sales increased marginally to Rs. 102.57 crore from Rs. 99.81 crore, a small growth of 2.8 per cent. The formulation revenue touched to Rs. 90.91 crore and its bulk drug sales reached at Rs. 37.03 crore during the quarter under review. Its employees cost increased by 46.2 per cent to Rs. 14.58 crore from Rs. 9.97 crore and R&D expenditure by 46.8 per cent to Rs. 12.23 crore from Rs. 8.33 crore in the corresponding period of last year.

For the first six months of FY11, Fresenius recorded net sales of Rs. 203.53 crore as against Rs. 197.78 crore in the same period of last year, a growth of 2.9 per cent. Its net profit, however, declined to Rs. 40.10 crore from Rs. 48.97 crore, a fall of 18.1 per cent. With lower net profit, its earnings per share worked out to Rs. 2.53 as compared to Rs. 2.80 in the last period. The promoters are holding 90 per cent of equity capital as at the end of September 2010.